taurine has been researched along with Drug Withdrawal Symptoms in 55 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic amphetamine use results in anxiety-like states after drug cessation." | 7.79 | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013) |
| "Acamprosate was discontinued in nine patients (1%) because of severe adverse events; only two cases were clearly linked to treatment (diarrhoea and dermatitis)." | 6.70 | Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. ( Preuss, U; Schuetz, C; Soyka, M, 2002) |
| "Chronic amphetamine use results in anxiety-like states after drug cessation." | 3.79 | The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. ( Gibula-Bruzda, E; Koltunowska, D; Kotlinska, JH, 2013) |
| " The effect of neramexane, a low-to-moderate affinity uncompetitive NMDA receptor antagonist, was examined on the development and expression of ethanol dependence (withdrawal-associated audiogenic seizures) and ethanol-induced conditioned place preference." | 3.72 | Effect of neramexane on ethanol dependence and reinforcement. ( Biala, G; Bochenski, M; Danysz, W; Kotlinska, J; Rafalski, P, 2004) |
| "Acamprosate was well tolerated during the entire course of the study." | 2.72 | Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. ( Boeijinga, P; Danel, T; Gendre, I; Landron, F; Luthringer, R; Muzet, M; Staner, L, 2006) |
| "Acamprosate was discontinued in nine patients (1%) because of severe adverse events; only two cases were clearly linked to treatment (diarrhoea and dermatitis)." | 2.70 | Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. ( Preuss, U; Schuetz, C; Soyka, M, 2002) |
| "Prevalence of alcohol dependence remains stable across time between 5-7% in men and 2-3% in women, corresponding to at least 1." | 2.44 | [Alcohol dependence: diagnosis and treatment]. ( Blanc, F; Perney, P; Rigole, H, 2008) |
| "Acamprosate is a proven effective intervention in the treatment of alcohol dependence." | 2.43 | Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. ( Geerlings, PJ; Koeter, MW; Lehert, P; van den Brink, W; Verheul, R, 2005) |
| "Acamprosate was generally well tolerated in placebo-controlled trials." | 2.40 | Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. ( Wagstaff, AJ; Wilde, MI, 1997) |
| "Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats." | 1.33 | Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. ( Cador, M; Koob, GF; Stinus, L; Zorrilla, EP, 2005) |
| " According to these observations, NR2B SSNAs are potent inhibitors of ethanol-withdrawal-induced neurotoxicity and considering that these agents have acceptable side effect profiles, they could be promising therapeutic candidates in the pharmacotherapy for physical signs of acute alcohol-withdrawal and associated neuronal damage." | 1.32 | NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. ( Farkas, S; Horváth, C; Kolok, S; Nagy, J; Szombathelyi, Z, 2004) |
| " Chronic administration of lower daily doses of acamprosate (100 and 200 mg/kg) blocked the increased ethanol consumption typically observed in rats after an imposed abstinence period." | 1.30 | Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. ( Durbin, P; Heyser, CJ; Koob, GF; Schulteis, G, 1998) |
| "Sleep-wake states were studied following withdrawal in 36 adult male wistar alcohol-dependent rats, after chronic administration of ethanol (10 g/kg/24 h) for 13 days." | 1.30 | Effects of muscimol or homotaurine on sleep-wake states in alcohol-dependent rats during withdrawal. ( Bajenaru, O; Dall'Ava-Santucci, J; Dinh-Xuan, AT; Emmanouilidis, E; Manicom, R; Poenaru, S; Rouhani, S; Tran, G, 1998) |
| "When acamprosate was given to alcohol-naive animals, it increased locomotor activity and body temperature transiently, in particular during the rats' active night phase." | 1.29 | Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. ( Putzke, J; Schöbitz, B; Spanagel, R; Stefferl, A; Zieglgänsberger, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.09) | 18.7374 |
| 1990's | 13 (23.64) | 18.2507 |
| 2000's | 27 (49.09) | 29.6817 |
| 2010's | 10 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koltunowska, D | 1 |
| Gibula-Bruzda, E | 1 |
| Kotlinska, JH | 1 |
| Müller, CA | 1 |
| Heinz, A | 1 |
| Higuchi, S | 2 |
| Mason, BJ | 2 |
| Ponizovskiy, PA | 1 |
| Gofman, AG | 1 |
| Yumoto, Y | 1 |
| Stoddard, J | 1 |
| Zummo, J | 1 |
| Soyka, M | 2 |
| Kotlinska, J | 2 |
| Bochenski, M | 2 |
| Hinton, DJ | 1 |
| Lee, MR | 1 |
| Jacobson, TL | 1 |
| Mishra, PK | 1 |
| Frye, MA | 1 |
| Mrazek, DA | 1 |
| Macura, SI | 1 |
| Choi, DS | 1 |
| Clark, DB | 1 |
| Kalk, NJ | 1 |
| Lingford-Hughes, AR | 1 |
| Mayer, S | 1 |
| Harris, BR | 1 |
| Gibson, DA | 1 |
| Blanchard, JA | 1 |
| Prendergast, MA | 1 |
| Holley, RC | 1 |
| Littleton, J | 2 |
| Dahchour, A | 4 |
| De Witte, P | 6 |
| Nagy, J | 1 |
| Horváth, C | 1 |
| Farkas, S | 1 |
| Kolok, S | 1 |
| Szombathelyi, Z | 1 |
| Smolka, MN | 2 |
| Kiefer, F | 2 |
| Mann, K | 3 |
| Stinus, L | 1 |
| Cador, M | 1 |
| Zorrilla, EP | 1 |
| Koob, GF | 4 |
| Boeijinga, PH | 1 |
| Parot, P | 1 |
| Soufflet, L | 1 |
| Landron, F | 2 |
| Danel, T | 2 |
| Gendre, I | 2 |
| Muzet, M | 2 |
| Demazières, A | 1 |
| Luthringer, R | 2 |
| Zakharova, E | 1 |
| Malyshkin, A | 1 |
| Kashkin, V | 1 |
| Neznanova, O | 1 |
| Sukhotina, I | 1 |
| Danysz, W | 2 |
| Bespalov, A | 1 |
| Verheul, R | 1 |
| Lehert, P | 1 |
| Geerlings, PJ | 1 |
| Koeter, MW | 1 |
| van den Brink, W | 1 |
| Biala, G | 1 |
| Rafalski, P | 1 |
| Lallemand, F | 1 |
| Ward, RJ | 1 |
| Staner, L | 1 |
| Boeijinga, P | 1 |
| Füllgrabe, MW | 1 |
| Vengeliene, V | 1 |
| Spanagel, R | 6 |
| Diehl, A | 1 |
| Perney, P | 1 |
| Rigole, H | 1 |
| Blanc, F | 1 |
| Contreras, E | 1 |
| Tamayo, L | 1 |
| Iwata, H | 1 |
| Matsuda, T | 1 |
| Lee, E | 1 |
| Yamagami, S | 1 |
| Baba, A | 1 |
| Jhamandas, KH | 1 |
| Marsala, M | 1 |
| Ibuki, T | 1 |
| Yaksh, TL | 1 |
| Putzke, J | 2 |
| Stefferl, A | 1 |
| Schöbitz, B | 1 |
| Zieglgänsberger, W | 4 |
| Tölle, TR | 1 |
| Wilde, MI | 1 |
| Wagstaff, AJ | 1 |
| Hölter, SM | 2 |
| Landgraf, R | 1 |
| Heyser, CJ | 1 |
| Schulteis, G | 1 |
| Durbin, P | 2 |
| Rouhani, S | 1 |
| Dall'Ava-Santucci, J | 1 |
| Bajenaru, O | 1 |
| Emmanouilidis, E | 1 |
| Tran, G | 2 |
| Manicom, R | 1 |
| Dinh-Xuan, AT | 1 |
| Poenaru, S | 1 |
| Kratzer, U | 1 |
| Schmidt, WJ | 1 |
| Cole, JC | 1 |
| Littleton, JM | 1 |
| Little, HJ | 1 |
| Myrick, H | 1 |
| Brady, KT | 1 |
| Malcolm, R | 1 |
| Korpi, E | 1 |
| Seppälä, T | 1 |
| Preuss, U | 1 |
| Schuetz, C | 1 |
| Siggins, GR | 1 |
| Ikeda, H | 1 |
| Gewiss, M | 1 |
| Heidbreder, C | 1 |
| Opsomer, L | 1 |
| Lhuintre, JP | 1 |
| Daoust, M | 1 |
| Moore, ND | 1 |
| Chretien, P | 1 |
| Saligaut, C | 1 |
| Bosimare, F | 1 |
| Hillemand, B | 1 |
| Liskow, BI | 1 |
| Goodwin, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642] | 30 participants (Anticipated) | Observational | 2006-04-30 | Completed | |||
| Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal[NCT00106106] | Phase 2 | 56 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 25
| Intervention | Ratio of glutamate to creatine (Mean) |
|---|---|
| Placebo | 1.350375 |
| Acamprosate | 1.166667 |
The ratio of glutamate to creatine was determined using magnetic resonance spectroscopy (MRS), a technique that complements magnetic resonance imaging (MRI). MRS is used to determine the concentration of brain metabolites, such as glutamate, in brain tissue. MRS utilizes a magnetic field to look at magnetic nuclei, which absorb and re-emit electromagnetic energy in the presence of the magnetic field. By looking at the peaks in the resultant spectra the structure and concentration of metabolites can be determined. (NCT00106106)
Timeframe: Day 4
| Intervention | Ratio of glutamate to creatine (Mean) |
|---|---|
| Placebo | 1.256772 |
| Acamprosate | 1.294178 |
16 reviews available for taurine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; | 2013 |
[Depression in alcohol addicted patients].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depressive Disorder | 2015 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Sy | 2015 |
The clinical pharmacology of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Rodentia; Secondary Prevention; Substa | 2014 |
Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
Topics: Acamprosate; Adult; Age Factors; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anxiety; Do | 2005 |
[Advances in the treatment of alcohol dependence: pharmacological relapse prevention].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Ethanol; Humans; Randomized Controlled Trials as Topic; | 2003 |
[Pharmacological relapse prevention in alcohol and tobacco dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Di | 2007 |
[Alcohol dependence: diagnosis and treatment].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Disulfiram; Humans; Motiv | 2008 |
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans | 1997 |
Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Drug Evaluation, Pre | 1997 |
Acamprosate for alcohol dependence?
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Controlled Clinical Trials as Topic; Humans; Substance | 1997 |
Animal models of craving for ethanol.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Behavior, Addictive; Conditioning, Opera | 2000 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carb | 2001 |
[Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Ethanol; Humans; Naltrexone; Narcoti | 1998 |
Acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Interactions; Humans; Substance Withdrawal Syndrom | 2002 |
Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review.
Topics: Alcohol Deterrents; Alcoholic Intoxication; Alcoholism; Antidepressive Agents, Tricyclic; Bromocript | 1987 |
5 trials available for taurine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study).
Topics: Acamprosate; Adult; Aged; Alcoholism; Double-Blind Method; Ethanol; Female; Humans; Japan; Long-Term | 2015 |
Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Arousal; Cerebral Cortex; Double-Blind Method; E | 2004 |
Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Central Nervous System Depressants; Compulsive P | 2006 |
Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; G | 2002 |
Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.
Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Indices; | 1985 |
34 other studies available for taurine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
Topics: Acamprosate; Amphetamine; Animals; Anxiety; Bridged Bicyclo Compounds; Dose-Response Relationship, D | 2013 |
Acamprosate, alcoholism, and abstinence.
Topics: Alcoholism; Ethanol; Female; Humans; Male; Substance Withdrawal Syndrome; Taurine | 2015 |
Oral and long-acting injectable naltrexone: removal of boxed warning for hepatotoxicity.
Topics: Alcoholism; Ethanol; Female; Humans; Male; Substance Withdrawal Syndrome; Taurine | 2015 |
[Pharmacotherapy of alcohol dependence].
Topics: Acamprosate; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Ambulatory Care; Anticonvu | 2008 |
The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Behavior, Animal; Central Nervous System Depressa | 2008 |
Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1.
Topics: Acamprosate; Animals; Brain; Equilibrative Nucleoside Transporter 1; Ethanol; gamma-Aminobutyric Aci | 2012 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorde | 2012 |
Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus.
Topics: Acamprosate; Animals; Animals, Newborn; Calcium Signaling; Dizocilpine Maleate; Ethanol; Female; Hip | 2002 |
Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods.
Topics: Acamprosate; Animals; Ethanol; Excitatory Amino Acids; Hippocampus; Male; Rats; Rats, Wistar; Substa | 2003 |
NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones.
Topics: Acamprosate; Alcohol Deterrents; Animals; Calcium; Cells, Cultured; Cerebral Cortex; Clone Cells; Cy | 2004 |
[Psychosocial treatment plus drug prophylaxis. Fewer recurrences after alcohol withdrawal].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Ethanol; Humans; Randomized | 2003 |
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learni | 2005 |
The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.
Topics: Acamprosate; Animals; Choice Behavior; Ethanol; Male; Memantine; Naloxone; Naltrexone; Narcotic Anta | 2004 |
Effect of neramexane on ethanol dependence and reinforcement.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Central Nervous System Depre | 2004 |
Production of reactive oxygen species following acute ethanol or acetaldehyde and its reduction by acamprosate in chronically alcoholized rats.
Topics: Acamprosate; Acetaldehyde; Alcohol Deterrents; Alcoholism; Animals; Disease Models, Animal; Ethanol; | 2005 |
Drug treatment for alcoholism today.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Disulfiram; Fructose; Humans; Na | 2005 |
Influence of age at drinking onset on the alcohol deprivation effect and stress-induced drinking in female rats.
Topics: Acamprosate; Age of Onset; Aging; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous Sys | 2007 |
Effects of taurine on tolerance to and dependence on morphine in mice.
Topics: Analgesia; Animals; Behavior, Animal; Drug Tolerance; Female; Humans; Mice; Morphine; Morphine Depen | 1984 |
Effect of ethanol on taurine concentration in the brain.
Topics: Alcoholism; Animals; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Ethanol; Humans; Male; Rats; Sl | 1980 |
Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine.
Topics: Amino Acids; Animals; Clonidine; Dizocilpine Maleate; Glutamic Acid; Glycine; Injections, Spinal; Ma | 1996 |
Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat.
Topics: Acamprosate; Alcohol Deterrents; Animals; Body Temperature; Drinking; Eating; Ethanol; Male; Motor A | 1996 |
The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal.
Topics: Acamprosate; Alcohol Deterrents; Animals; Central Nervous System Depressants; Cerebellum; Convulsant | 1996 |
Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Conditioning, Operant; Dose-Response Relations | 1997 |
Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Central Nervous System Depressants; Cond | 1998 |
Effects of muscimol or homotaurine on sleep-wake states in alcohol-dependent rats during withdrawal.
Topics: Alcoholic Intoxication; Alcoholism; Animals; Behavior, Animal; Body Weight; Central Nervous System D | 1998 |
The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
Topics: Acamprosate; Alcohol Deterrents; Analgesics, Opioid; Animals; Conditioning, Psychological; Drug Inte | 1998 |
Acamprosate decreases the hypermotility during repeated ethanol withdrawal.
Topics: Acamprosate; Alcohol Deterrents; Animals; Central Nervous System Depressants; Ethanol; Glutamic Acid | 1999 |
Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze.
Topics: Acamprosate; Alcohol Deterrents; Animals; Anxiety; Central Nervous System Depressants; Ethanol; Expl | 2000 |
Taurine blocks the glutamate increase in the nucleus accumbens microdialysate of ethanol-dependent rats.
Topics: Alcoholism; Animals; Arginine; Central Nervous System Depressants; Ethanol; gamma-Aminobutyric Acid; | 2000 |
Pharmacological validation of a new animal model of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Nalt | 2000 |
Drug treatments for alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Naltrexone; Substance Withdrawal Sy | 2002 |
Potential neuroprotective effects of acamprosate.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Brain; Humans; Neuroprotective Agents; Substan | 2002 |
Effects of taurine on alcohol withdrawal.
Topics: Alcoholism; Chronic Disease; Ethanol; Humans; Substance Withdrawal Syndrome; Taurine | 1977 |
Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour.
Topics: Acamprosate; Administration, Inhalation; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Anima | 1991 |